KR20240164594A - 설계된 사이토카인 조성물 및 사용 방법 - Google Patents

설계된 사이토카인 조성물 및 사용 방법 Download PDF

Info

Publication number
KR20240164594A
KR20240164594A KR1020247026696A KR20247026696A KR20240164594A KR 20240164594 A KR20240164594 A KR 20240164594A KR 1020247026696 A KR1020247026696 A KR 1020247026696A KR 20247026696 A KR20247026696 A KR 20247026696A KR 20240164594 A KR20240164594 A KR 20240164594A
Authority
KR
South Korea
Prior art keywords
designed
cell
cytokine
sequence
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247026696A
Other languages
English (en)
Korean (ko)
Inventor
스콧 보이켄
마르크 라조이
타데우스 엠 다벤포트
하웰 모페트
브라이언 바이츠너
앤드류 호웬 응
폴 조셉 샘플
Original Assignee
아웃페이스 바이오, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아웃페이스 바이오, 인크. filed Critical 아웃페이스 바이오, 인크.
Publication of KR20240164594A publication Critical patent/KR20240164594A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR1020247026696A 2022-01-11 2023-01-11 설계된 사이토카인 조성물 및 사용 방법 Pending KR20240164594A (ko)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202263298623P 2022-01-11 2022-01-11
US63/298,623 2022-01-11
US202363479178P 2023-01-09 2023-01-09
US202363479177P 2023-01-09 2023-01-09
US202363479176P 2023-01-09 2023-01-09
US63/479,177 2023-01-09
US63/479,176 2023-01-09
US63/479,178 2023-01-09
PCT/US2023/060508 WO2023137346A2 (en) 2022-01-11 2023-01-11 Designed cytokine compositions and methods of use

Publications (1)

Publication Number Publication Date
KR20240164594A true KR20240164594A (ko) 2024-11-19

Family

ID=87279672

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247026696A Pending KR20240164594A (ko) 2022-01-11 2023-01-11 설계된 사이토카인 조성물 및 사용 방법

Country Status (10)

Country Link
US (1) US20250223330A1 (https=)
EP (1) EP4463469A4 (https=)
JP (1) JP2025502205A (https=)
KR (1) KR20240164594A (https=)
CN (1) CN119053616A (https=)
AU (1) AU2023208031A1 (https=)
CA (1) CA3248134A1 (https=)
IL (1) IL314226A (https=)
MX (1) MX2024008642A (https=)
WO (1) WO2023137346A2 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL325764A (en) * 2023-07-13 2026-03-01 Outpace Bio Inc Designed compositions of interleukin-2 cytokine and methods of use
WO2025212606A1 (en) * 2024-04-01 2025-10-09 Bio-Techne Corporation Synthetic il-2 polypeptides and conjugates, compositions, and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210025522A (ko) * 2018-06-25 2021-03-09 유니버시티 오브 워싱톤 강력하고 선택적인 인터루킨 모방체의 드 노보 디자인
MX2021000801A (es) * 2018-07-24 2021-04-12 BioNTech SE Agonistas de il2.
CN118510795A (zh) * 2022-01-07 2024-08-16 苏州克睿基因生物科技有限公司 新型白介素-2多肽

Also Published As

Publication number Publication date
US20250223330A1 (en) 2025-07-10
IL314226A (en) 2024-09-01
CA3248134A1 (en) 2023-07-20
MX2024008642A (es) 2024-09-23
EP4463469A2 (en) 2024-11-20
AU2023208031A1 (en) 2024-08-29
EP4463469A4 (en) 2026-01-14
WO2023137346A2 (en) 2023-07-20
JP2025502205A (ja) 2025-01-24
CN119053616A (zh) 2024-11-29
WO2023137346A3 (en) 2023-11-16

Similar Documents

Publication Publication Date Title
JP6783797B2 (ja) 抗がん融合ポリペプチド
JP6041799B2 (ja) Ｔｒａｉｌｒ２特異的多量体足場
KR102653906B1 (ko) 편향된 il2 뮤테인 방법 및 조성물
JP7832111B2 (ja) Ｇ１２ｄ突然変異ｒａｓに対するｈｌａクラスｉ拘束性ｔ細胞受容体
CN111511911A (zh) 表达特异性地识别人间皮素的细胞表面分子、il-7和ccl19的免疫活性细胞
KR20240164594A (ko) 설계된 사이토카인 조성물 및 사용 방법
KR20220131529A (ko) 변경된 icd stat 신호전달을 갖는 cd122
JP2026041861A (ja) Ｉｌ２オルソログおよび使用法
CN115244075A (zh) 针对含有g12v突变的ras的hla ii类限制性t细胞受体
CN112533629A (zh) 结合使用il-10药剂与嵌合抗原受体细胞疗法的组合物和方法
WO2025015322A1 (en) Designed interleukin-2 cytokine compositions and methods for use
TW202525858A (zh) 抗間皮素嵌合抗原受體及使用方法
CN117209584A (zh) 一种刺激细胞同时产生干扰素、干扰素刺激基因产物和炎症因子的多肽、重组多肽及其用途
CA3238005A1 (en) Chimeric antigen receptors
KR20240004453A (ko) 변형된 과립구 집락-자극 인자(g-csf) 및 이에 결합하는 키메라 사이토카인 수용체
TW202434618A (zh) 經設計之細胞激素組合物及使用方法
WO2022111475A1 (zh) 一种识别hpv抗原的tcr
WO2025207624A1 (en) Compositions and methods useful in the treatment of autoimmune disease
WO2022007885A1 (zh) 融合多肽和多肽二聚体及其用途
CN120842359A (zh) 白介素-15突变体及其用途
HK1249526B (en) Anti-cancer fusion polypeptide

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000